Two-Drug attack tested for stubborn blood cancer

This study tested whether combining two drugs, daratumumab and ibrutinib, works better than ibrutinib alone for patients whose chronic lymphocytic leukemia (CLL) has come back or stopped responding to previous treatments. Daratumumab helps the immune system target cancer cells, while ibrutinib blocks a protein that helps cancer cells grow. The trial was small and ended early, aiming to see if the combination could lead to better responses and reduce traces of cancer in the body.